Clinical Trial Update: Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.). [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluated Anecortave acetate (15 mg) for idiopathic perifoveal telangiectasia, and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Macular Telangiectasia Type 2

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Idiopathic Perifoveal Telangiectasia | Phase 2 | Status: COMPLETED